Neratinib - HKI 272

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1526

CAS [698387-09-6]

MF C30H29ClN6O3
MW 557.04

Purity: 98%
Soluble in 0.1N HCl(aq) and DMSO

Neratinib

Description

An irreversible tyrosine kinase inhibitor with activity against HER2 and EGFR kinases; a therapeutic agent under investigation for the treatment breast cancer and other solid tumors.

SK Rabindran et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004, 64(11), 3958–65.

Y Minami et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007, 26(34), 5023–7.

A Ocaña and E Amir. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev. 2009, 5(8), 685-691.

Angiogenesis Cell Signaling & Oncology EGFR ErbB2-HER2 JAK-STAT RTK class I; EC 2.7.10.1

EGFR and ErbB-2/HER2 tyrosine kinase inhibitor

Chemical name

(E)-4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide

Parent CAS No.

[698387-09-6]

产品资料